Why is Brawn Biotech falling/rising?

As of 02-Jul, Brawn Biotech Ltd's stock price is currently at 19.24, reflecting an increase of 0.89 or 4.85%. The stock has shown a strong performance recently, gaining 19.06% over the last four days and outperforming its sector by 4.08% today. However, despite this short-term rise, the company has significant long-term challenges, including operating losses and a weak ability to service its debt, as indicated by a poor EBIT to Interest ratio of -1.29. The stock has underperformed over the past year, with a return of -30.01%, while net sales have declined at an annual rate of -22.97%, contributing to its negative sentiment among investors.
In the broader market context, Brawn Biotech's recent 1-week return of +14.93% significantly outpaces the Sensex's +0.79%, indicating a strong short-term recovery relative to the benchmark. However, the stock's year-to-date performance remains concerning, with a decline of -9.71% compared to the Sensex's +6.75%. This juxtaposition highlights the volatility and risk associated with Brawn Biotech, as it has not only struggled with long-term growth but also faced a substantial drop in investor participation, evidenced by an 86.57% decrease in delivery volume. Overall, while the stock is experiencing a short-term rise, its long-term fundamentals and market performance suggest ongoing challenges.